Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2013 3
2014 8
2015 18
2016 8
2017 4
2018 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J. Gerhauser C, et al. Among authors: koop c. Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016. Cancer Cell. 2018. PMID: 30537516 Free PMC article.
Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.
Wilczak W, Wittmer C, Clauditz T, Minner S, Steurer S, Büscheck F, Krech T, Lennartz M, Harms L, Leleu D, Ahrens M, Ingwerth S, Günther CT, Koop C, Simon R, Jacobsen F, Tsourlakis MC, Chirico V, Höflmayer D, Vettorazzi E, Haese A, Steuber T, Salomon G, Michl U, Budäus L, Tilki D, Thederan I, Fraune C, Göbel C, Henrich MC, Juhnke M, Möller K, Bawahab AA, Uhlig R, Adam M, Weidemann S, Beyer B, Huland H, Graefen M, Sauter G, Schlomm T. Wilczak W, et al. Among authors: koop c. Eur Urol. 2018 Sep;74(3):376-386. doi: 10.1016/j.eururo.2018.05.034. Epub 2018 Jun 13. Eur Urol. 2018. PMID: 29908878
Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer.
Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, Oakes C, Zucknick M, Lipka DB, Weischenfeldt J, Feuerbach L, Cowper-Sal Lari R, Lupien M, Brors B, Korbel J, Schlomm T, Tanay A, Sauter G, Gerhäuser C, Plass C; ICGC Early Onset Prostate Cancer Project. Brocks D, et al. Among authors: koop c. Cell Rep. 2014 Aug 7;8(3):798-806. doi: 10.1016/j.celrep.2014.06.053. Epub 2014 Jul 24. Cell Rep. 2014. PMID: 25066126 Free article.
βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.
Hinsch A, Chaker A, Burdelski C, Koop C, Tsourlakis MC, Steurer S, Rink M, Eichenauer TS, Wilczak W, Wittmer C, Fisch M, Simon R, Sauter G, Büschek F, Clauditz T, Minner S, Jacobsen F. Hinsch A, et al. Among authors: koop c. Hum Pathol. 2017 Mar;61:210-220. doi: 10.1016/j.humpath.2016.11.005. Epub 2016 Dec 24. Hum Pathol. 2017. PMID: 28025079
p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.
Burdelski C, Dieckmann T, Heumann A, Hube-Magg C, Kluth M, Beyer B, Steuber T, Pompe R, Graefen M, Simon R, Minner S, Tsourlakis MC, Koop C, Izbicki J, Sauter G, Krech T, Schlomm T, Wilczak W, Lebok P. Burdelski C, et al. Among authors: koop c. Tumour Biol. 2016 Sep;37(9):12655-12663. doi: 10.1007/s13277-016-5167-y. Epub 2016 Jul 21. Tumour Biol. 2016. PMID: 27444279
High mitochondria content is associated with prostate cancer disease progression.
Grupp K, Jedrzejewska K, Tsourlakis MC, Koop C, Wilczak W, Adam M, Quaas A, Sauter G, Simon R, Izbicki JR, Graefen M, Huland H, Schlomm T, Minner S, Steurer S. Grupp K, et al. Among authors: koop c. Mol Cancer. 2013 Nov 21;12(1):145. doi: 10.1186/1476-4598-12-145. Mol Cancer. 2013. PMID: 24261794 Free PMC article.
NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.
Grupp K, Ospina-Klinck D, Tsourlakis MC, Koop C, Wilczak W, Adam M, Simon R, Sauter G, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A. Grupp K, et al. Among authors: koop c. Prostate. 2014 Jul;74(10):1012-22. doi: 10.1002/pros.22816. Epub 2014 May 1. Prostate. 2014. PMID: 24789172
TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S, Mayer PS, Adam M, Krohn A, Koop C, Ospina-Klinck D, Tehrani AA, Simon R, Tennstedt P, Graefen M, Wittmer C, Brors B, Plass C, Korbel J, Weischenfeldt J, Sauter G, Huland H, Tsourlakis MC, Minner S, Schlomm T. Steurer S, et al. Among authors: koop c. Eur Urol. 2014 Dec;66(6):978-81. doi: 10.1016/j.eururo.2014.06.027. Epub 2014 Jul 9. Eur Urol. 2014. PMID: 25015038
Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome.
Grupp K, Hofmann B, Kutup A, Bachmann K, Bogoevski D, Melling N, Uzunoglu FG, El Gammal AT, Koop C, Simon R, Steurer S, Krech T, Burdak-Rothkamm S, Jacobsen F, Sauter G, Izbicki J, Wilczak W. Grupp K, et al. Among authors: koop c. BMC Cancer. 2018 Nov 12;18(1):1106. doi: 10.1186/s12885-018-5032-z. BMC Cancer. 2018. PMID: 30419865 Free PMC article.
38 results